Filing Summary
Entity and period: The supplied filing is PerkinElmer, Inc.’s unaudited Form 10-Q for the quarter ended June 29, 2014, with six-month results compared with the period ended June 30, 2013. This does not match the request metadata identifying Revvity, Inc.; verify the intended issuer before relying on this summary.
Business Context and Results
PerkinElmer reported two continuing-operation segments: Human Health, serving diagnostics and research markets, and Environmental Health, serving environmental, industrial, and laboratory-services markets. Q2 revenue growth came mainly from diagnostics and laboratory services. Weak academic research demand and softer environmental and industrial product revenue partly offset that growth.
| Metric | Q2 2014 | Q2 2013 | First half 2014 | First half 2013 |
|---|---|---|---|---|
| Revenue | $556.2 million | $540.7 million | $1,086.8 million | $1,043.6 million |
| Gross margin | 44.6% | 44.7% | 44.5% | 44.7% |
| Operating income, continuing operations | $69.6 million | $40.2 million | $121.4 million | $76.9 million |
| Income from continuing operations | $52.0 million | $27.3 million | $87.0 million | $60.0 million |
| Net income | $50.5 million | $27.9 million | $84.7 million | $60.1 million |
| Diluted EPS | $0.44 | $0.25 | $0.74 | $0.53 |
- Q2 revenue increased 3%; first-half revenue rose 4%. Human Health revenue increased 3% in Q2 and 5% in the first half; Environmental Health revenue increased 2% and 3%, respectively.
- Q2 operating income rose 73% as reported, helped by materially lower restructuring charges versus 2013 and cost-control and productivity initiatives. Gross margin slipped 11 basis points in Q2 and 16 basis points for the first half, reflecting product mix and, for the first half, pricing pressure.
- Q2 continuing-operations effective tax rate was 14.3%, versus 0.3% a year earlier. The first-half 2014 rate was 14.0%, compared with a tax benefit rate of 15.5% in 2013; prior-year discrete tax benefits were larger.
Cash Flow, Balance Sheet, and Capital Allocation
- First-half operating cash flow from continuing operations was $122.6 million, versus $39.9 million in 2013. Capital expenditures were $14.4 million, compared with $22.9 million. Cash and equivalents increased to $205.3 million from $173.2 million at year-end.
- At June 29, 2014, current assets were $1,080.6 million and current liabilities $578.6 million; working capital was $502.1 million. Total debt was approximately $895.3 million, comprising $1.1 million short-term and $894.3 million long-term debt. Cash less debt was approximately negative $690 million.
- The company refinanced its $700 million revolving facility in January 2014, extending initial maturity to January 2019. It had $358 million drawn, $329.8 million available after letters of credit, and reported covenant compliance. The $500 million 2021 notes carry a 5% coupon; financing-lease obligations were $39.8 million.
- First-half financing cash use was $76.7 million, including $39.0 million of share repurchases and $15.8 million of dividends. The quarterly dividend remained $0.07 per share; the board declared the same amount for Q3.
Outlook, Commentary, and Risks
- Management described demand growth in prenatal, newborn, and infectious-disease screening, particularly in emerging markets, and continued growth in OneSource laboratory services. It also cited research-market weakness in Europe and China, including Chinese government funding delays, and softer environmental and industrial product demand.
- No consolidated revenue or earnings guidance is provided in the supplied filing text. Management expected restructuring actions executed in 2013 to generate more than $9 million in annual savings beginning in fiscal 2015, primarily through lower R&D expense.
- In May 2014, management approved closing a U.S. microarray-based diagnostic testing laboratory, citing inadequate payer reimbursement and the significant investment needed to compete. Discontinued operations recorded a first-half pretax loss of $3.1 million, including workforce-reduction costs.
- After quarter-end, the company paid $7.0 million into escrow to settle the long-running Enzo litigation; $3.7 million had been accrued. Q2 included $3.4 million of litigation-preparation expense. Environmental remediation accruals were $12.0 million; management said estimates are uncertain and may change as investigations progress.
- Other risks highlighted include government and customer funding uncertainty, foreign-exchange and variable-rate interest exposure, international operations, competition and product development, regulatory compliance, litigation, debt and covenant constraints, and possible impairment of goodwill or other intangible assets. About 60% of business was conducted outside the United States.
Most Important Facts to Verify
- Confirm the intended issuer: the filing identifies PerkinElmer, Inc., not Revvity, Inc.
- Reconcile operating-income growth with the sharp year-over-year reduction in restructuring charges and assess the sustainability of cost savings and margins.
- Review cash conversion, working-capital movements, debt maturities, variable-rate exposure, and the availability of revolving credit.
- Confirm the final accounting and cash impact of the Enzo settlement, and monitor environmental, tax, and other legal contingencies.
- Assess whether growth in diagnostics and laboratory services can offset research and environmental/industrial weakness; the filing gives no consolidated forward financial guidance.